His primary areas of investigation include Internal medicine, Steatohepatitis, Fatty liver, Cirrhosis and Gastroenterology. Many of his studies on Internal medicine apply to Endocrinology as well. His Steatohepatitis study is associated with Disease.
His study in Fatty liver is interdisciplinary in nature, drawing from both Proinflammatory cytokine, Steatosis and Mitochondrion. His Cirrhosis study incorporates themes from Liver disease, Metabolic syndrome, Liver transplantation and Pathology. His study looks at the relationship between Gastroenterology and topics such as Fibrosis, which overlap with Predictive value of tests.
The scientist’s investigation covers issues in Internal medicine, Gastroenterology, Fatty liver, Steatohepatitis and Cirrhosis. Quentin M. Anstee regularly links together related areas like Endocrinology in his Internal medicine studies. His work carried out in the field of Gastroenterology brings together such families of science as Diabetes mellitus, Body mass index, Obeticholic acid and Non invasive.
His work is dedicated to discovering how Fatty liver, Liver disease are connected with Surgery and other disciplines. His Cirrhosis research includes themes of TM6SF2, Bioinformatics and Pathology. Quentin M. Anstee works mostly in the field of Disease, limiting it down to concerns involving Obesity and, occasionally, Epidemiology.
Quentin M. Anstee mainly focuses on Internal medicine, Fatty liver, Steatohepatitis, Gastroenterology and Fibrosis. His Liver biopsy, Non alcoholic, Nonalcoholic fatty liver disease and Liver disease study in the realm of Internal medicine interacts with subjects such as In patient. His Fatty liver research is under the purview of Disease.
His research investigates the connection between Disease and topics such as Obesity that intersect with issues in Health policy and Epidemiology. His Steatohepatitis research incorporates elements of Cancer research, Genome-wide association study, Cirrhosis, Metabolic syndrome and Type 2 Diabetes Mellitus. The concepts of his Gastroenterology study are interwoven with issues in Biopsy, Adverse effect, Obeticholic acid and Non invasive.
Quentin M. Anstee mainly investigates Internal medicine, Fatty liver, Steatohepatitis, Cirrhosis and Fibrosis. His work in Internal medicine addresses subjects such as Gastroenterology, which are connected to disciplines such as Adverse effect. He has included themes like Cross-sectional study and Cohort in his Fatty liver study.
His studies in Steatohepatitis integrate themes in fields like Cancer research and Immunotherapy. His work carried out in the field of Fibrosis brings together such families of science as Meta-analysis and Nonalcoholic fatty liver disease. His Disease study incorporates themes from Type 2 Diabetes Mellitus and Intensive care medicine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Zobair Younossi;Quentin M. Anstee;Milena Marietti;Timothy Hardy;Timothy Hardy.
Nature Reviews Gastroenterology & Hepatology (2018)
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.
Quentin M. Anstee;Giovanni Targher;Christopher P. Day.
Nature Reviews Gastroenterology & Hepatology (2013)
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
Mohammed Eslam;Philip N. Newsome;Shiv K. Sarin;Quentin M. Anstee.
Journal of Hepatology (2020)
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management
Stuart McPherson;Stuart McPherson;Tim Hardy;Elsbeth Henderson;Alastair D. Burt;Alastair D. Burt.
Journal of Hepatology (2015)
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu;Vlad Ratziu;Stephen A. Harrison;Sven Francque;Pierre Bedossa.
Mouse models in non-alcoholic fatty liver disease and steatohepatitis research
Quentin M. Anstee;Robert D. Goldin.
International Journal of Experimental Pathology (2006)
Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030
Chris Estes;Quentin M. Anstee;Maria Teresa Arias-Loste;Heike Bantel.
Journal of Hepatology (2018)
Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.
Leon A Adams;Quentin M Anstee;Herbert Tilg;Giovanni Targher.
From NASH to HCC: current concepts and future challenges.
Quentin M Anstee;Quentin M Anstee;Helen L Reeves;Helen L Reeves;Elena Kotsiliti;Olivier Govaere.
Nature Reviews Gastroenterology & Hepatology (2019)
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
Yang-Lin Liu;Helen L Reeves;Alastair D Burt;Dina Tiniakos.
Nature Communications (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: